Publications by authors named "A Nanzer"
Background: Benralizumab has been reported to lead to clinical remission of severe eosinophilic asthma (SEA) at 1 year in some patients. However, whether this is maintained over a longer term remains unclear. Additionally, the impact of pulmonary and extrapulmonary comorbidities on the ability to meet remission is poorly understood.
View Article and Find Full Text PDFBackground: Dupilumab is an anti-IL-4R monoclonal antibody (mAb) with proven efficacy in severe eosinophilic asthma (SEA). A suboptimal response to anti-IL-5/5R mAbs is seen in some patients with ongoing evidence of type 2 (T2) inflammation.
Objective: To understand whether targeting IL-13 pathways with dupilumab in these patients may lead to better clinical outcomes.
Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis.
J Allergy Clin Immunol Pract
March 2024
Article Synopsis
- Eosinophilic granulomatosis with polyangiitis (EGPA) is a serious condition causing inflammation, and benralizumab is an antibody treatment that helps reduce eosinophils, but its long-term effects were initially unclear.
- A study analyzed 70 EGPA patients treated with benralizumab to see how effective it was at achieving clinical remission after 1 and 2 years.
- Results showed that 67% of patients achieved remission after 1 year and many were able to stop using corticosteroids, indicating that benralizumab is both effective and well-tolerated in managing EGPA.*